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ABSTRACT 
 
Aims: To perform a systematic review and meta-analysis of randomized clinical trials (RCT) 
comparing the effectiveness of drugs targeting mitochondrial function vs. placebo in patients with 
ST-segment elevation myocardial infarction (STEMI) undergoing mechanical coronary reperfusion. 
Methods: Inclusion criteria: RCTs enrolling STEMI patients treated with primary percutaneous 
coronary intervention (PCI) and comparing drugs targeting mitochondrial function vs. placebo. 
Odds ratios (OR) were computed from individual studies and pooled with random-effect 
metanalysis.  
Results: Fifteen studies were identified involving 5680 patients. When compared with placebo, 
drugs targeting mitochondrial component/pathway were not associated with significant reduction of 
cardiovascular and all-cause mortality (OR 0.9, 95%CI 0.7-1.17 and OR 0.92, 95%CI 0.69-1.23, 
respectively). However, these agents significantly reduced hospital admission for heart failure (HF) 
(OR 0.64; 95%CI 0.45-0.92) and increased left ventricular ejection fraction (LVEF) (OR 1.44; 95% 
CI 1.15-1.82). After analysis for subgroups according to the mechanism of action, drugs with 
direct/selective action did not reduce any outcome. Conversely, those with indirect/unspecific 
action showed a significant effect on cardiovascular mortality (0.65, 95%CI 0.46-0.92), all-cause 
mortality (OR 0.69, 95%CI 0.52-0.92), hospital readmission for HF (OR 0.41, 95%CI 0.28-0.6) and 
LVEF (OR 1.49, 95%CI 1.09-2.05). 
Conclusions: Administration of drugs targeting mitochondrial function in STEMI patients 
undergoing primary PCI appear to have no effect on mortality, but may reduce hospital readmission 
for HF. The drugs with a broad-spectrum mechanism of action seem to be more effective in 
reducing adverse events. 
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INTRODUCTION 
 
Despite timely and complete reperfusion by primary percutaneous coronary intervention (PCI), 
mortality and morbidity are still high in patients with large ST-segment elevation myocardial 
infarction (STEMI) [1]. Data from animal models suggested that the process of restoring coronary 
blood flow itself paradoxically induces myocardial injury and contributes to final infarct size (IS) 
[2-4]. This phenomenon is called “reperfusion injury” (RI) and it is thought to mitigate the full 
benefit of reperfusion [2-4]. Although several aspects remain obscure and definitive evidence in 
humans is lacking, experimental studies have established that altered mitochondrial function is 
strongly involved in the RI genesis [4-5]. As such, several randomized clinical trials (RCT) 
assessed the effectiveness of novel agents capable of targeting mitochondrial function with the aim 
to reduce IS and improve outcome [4-19]. These studies have reported conflicting results using 
surrogate markers and none was individually adequately powered for hard endpoints [6-19]. 
Systematic reviews employing meta-analytic techniques provide quantitative and objective means 
to pool and assess available clinical evidence, emphasizing internal validity and homogeneity, while 
affording increased statistical power for hypothesis testing. Thus, the aim of this study was to 
perform a systematic review and meta-analysis of RCTs comparing drugs targeting mitochondrial 
function vs. placebo in patients undergoing primary PCI for STEMI.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
METHODS 
 
We developed a systematic review and meta-analysis following Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) amendment to the Quality of Reporting of Meta-
analyses (QUOROM) statement [20-23]. The protocol for this study was previously published on an 
international prospective register for systematic reviews (PROSPERO) with the number: 
CRD42016033085. 
Search strategy 
Two expert cardiologists (RP, SB) independently and systematically searched (MESH strategy) 
MEDLINE, Cochrane Library, Google Scholar and Biomed Central for RCTs comparing drugs 
against the RI vs. placebo in patients with STEMI. The terms searched were: (reperfusion injury) 
AND ((PCI) OR (percutaneous coronary intervention) OR (ST elevation myocardial infarction) OR 
(STEMI) OR (myocardial infarction)). Details of the search strategy are reported in the appendix 
online. The research was carried out in December 2015. 
 
Selection criteria 
Shortlisted studies were retrieved as full articles and appraised independently by two unblinded 
reviewers (GC, FO), with divergences resolved after consensus, according to the following 
inclusion criteria: i) English language; ii) enrollment of STEMI patients; iii) reperfusion strategy by 
primary PCI; iv) randomized treatment allocation; v) comparison of agent/drug against RI vs. 
placebo/gold standard treatment; vi) at least 50 patients. Exclusion criteria were: i) duplicate reports 
failing to report additional or extended clinical outcomes, ii) lack of outcome data beyond 
hospitalization; iii) equivocal or non-random treatment allocation. Finally, selected studies were 
analysed by two independent reviewers (PP, GM) to establish if the experimental drug did or did 
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not have a mechanism of action targeting mitochondrial function (detailed description in the 
supplemental appendix). They checked the following items for each drug/agent: pharmacological 
targets, location or not of the targets in mitochondria, activation or not of mitochondrial pathways, 
selectivity and exclusivity in the action against mitochondria. This adjudication was performed 
according to a recent overview [5] and after revision of all available information regarding the 
agent/drug. The studies were classified into three groups: i) direct/selective mechanism of action 
targeting a mitochondrial component/pathway; ii) indirect/unspecific mechanism of action targeting 
mitochondrial component/pathway; and iii) mechanism of action not targeting mitochondria. The 
present study focused its attention on the first two groups. 
 
Data abstraction, endpoints, contact with authors 
The reviewers (RP, SB, GC, FO) independently abstracted data. In the case of incomplete 
or unclear data, authors were contacted obtaining missing information. In addition, for the 
studies of Jones et al. and Lonborg et al., a longer follow-up was available (36 vs. 12 
months and 12 vs. 1 months, respectively) and it was included in our analysis [16-17]. The 
primary endpoint of the analysis was the incidence of cardiovascular death. Secondary 
endpoints were: all-cause death, hospital readmission for heart failure (HF) and left 
ventricular ejection fraction (LVEF). We performed a pre-hoc stratification of studies 
according to mechanism of action (direct/selective vs. indirect/unspecific). Additional 
analyses were performed after stratification of studies according to the following criteria: 
i) administration of cyclosporine, ii) administration of nicorandil, iii) follow-up length <12 
vs. ≥12 months iv) indirect/unspecific drugs after exclusion of the study of Pizarro et al. 
[15]. 
 
Internal validity and quality appraisal  
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Two unblinded reviewers (RP, SB) evaluated the quality of included studies using pre-
specified electronic forms that were piloted over the first 3 cases. No studies were 
excluded on the basis of this analysis. The same authors independently verified the 
eventual exclusion of some studies analyzing references from all the papers. Modifying the 
MOOSE item list in order to take into account the specific features of included studies, we 
separately abstracted and appraised study design, setting and data sources. Hence, 
following the Cochrane Collaboration approach we evaluated for each RCT the risk of 
analytical, selection, adjudication, detection, and attrition bias (expressed as low, 
moderate, or high risk of bias, as well as incomplete reporting leading to inability to 
ascertain the underlying risk of bias). 
 
Data analysis and synthesis 
Continuous variables were reported as mean (±SD) or median [interquartile range]. 
Categorical variables were expressed as number and percentage. The endpoints were 
expressed as an odds ratio (OR). oint estimates and standard errors were calculated and 
combined by the generic inverse variance method [24], computing risk estimates with 95% 
confidence intervals according to logarithmic transformation of the hazard measures. 
Considering the high likelihood of between-study variance, we used a random effect 
model. Statistical heterogeneity was assessed using the Cochran’s Q test. This statistic was 
complemented with the I
2
 statistic, which quantifies the proportion of total variation across 
studies that is due to heterogeneity rather than chance. A value of I
2
 of 0 to 25 % 
represents insignificant heterogeneity, 26 to 50 % low heterogeneity, 51 to 75 % moderate 
heterogeneity, and >75 % high heterogeneity [25]. To test the difference between sub-
group analyses the Chi
2
 test has been used. Finally, random effect meta-regression analysis 
was performed to assess the effect of several potential confounding factors (sex, anterior 
MI, glycoprotein IIb/IIa inhibitor, baseline TIMI flow 0-1, smoking, dyslipidemia, prior 
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MI, stent implantation, thrombus-aspiration, diabetes, hypertension) on results. Publication 
bias was appraised by graphical valuation of funnel plots and through Begg and Mazumdar 
rank correlation, Egger’s regression intercept, and Duval and Tweedie trim and fill [26]. 
Prometa (Internovi, Cesena, Itay) and RevMan 5 (The Cochrane Collaboration, The 
Nordic Cochrane Centre, Copenhagen, Denmark) software were used for statistical 
analyses. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
RESULTS 
 
Search results and study selection 
The database search yielded 948 citations (Figure 1). Shortlisted citations were 
retrieved and checked at the title/abstract level excluding 889 papers (Figure 1). Complete 
articles for the remaining 45 studies were checked for compliance to inclusion/exclusion 
criteria (Figure 1). Finally, we identified 25 eligible trials meeting our inclusion/exclusion 
criteria of which 10 were excluded because the experimental drug was not targeting 
mitochondria. A total of 15 studies were included in qualitative and quantitative meta-
analysis (Table 1, Figure 1). Overall, 8 (53%) studies were double blind [7, 9-12, 16-18], 4 
(27%) single blind [6, 13, 15] and 3 (20%) open label [8, 14,19]. Of note, reviewers 
largely debated about classification of the study by Lincoff et al. and inclusion of the study 
by Pizarro et al. [9,15] (see online supplemental for more details). Finally, they decided to 
classify the first as direct/selective mechanism of action and to include the second, but as 
indirect/unspecific mechanism of action.   
 
Baseline characteristics 
Overall, 5864 patients were randomized and 5680 (97%) patients were included in 
the final analysis (Table 1). Six studies randomized 1774 subjects to treatment with an 
experimental drug with direct/selective mechanism of action against mitochondrial 
component/pathways (Table 1). Three studies used cyclosporine, whereas in 3 studies 
other drugs were administered (delcasertib, MTP-131, TRO40303). Conversely, 9 studies 
randomized 1329 patients to an experimental drug with an indirect/unspecific mechanism 
of action against mitochondrial component/pathways (metoprolol, atrial natriuretic 
peptide, nicorandil, exenatide, doxycycline, nitrite). The mean age of the population was 
61±1 years old (Table 1). Anterior MI was present in 3802 (66%) patients. Baseline TIMI 
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flow grade was 0-1 in 4693 (82%) patients. The use of glycoprotein IIb/IIIa inhibitors and 
thromboaspiration was relatively common (37% and 35% of patients, respectively). 
 
Cardiovascular mortality 
Overall, the pooled effect estimate analysis showed a non-significant reduction in 
cardiovascular mortality (OR 0.9, 95%CI 0.7-1.17, p=0.4, I
2
=10%) in patients randomly 
allocated to receive drugs targeting mitochondrial function (Figure 2). Interestingly, after 
stratification of studies according to the mechanism of action, we found that 
indirect/unspecific drugs had a significant effect (OR 0.65, 95%CI 0.46-0.92, p=0.02, 
I
2
=0%), whereas the direct/selective ones did not (OR 1.18, 95%CI 0.86-1.61, p=0.3, 
I
2
=3%) (Figure 2). The difference between the two subgroups reached statistical 
significance (p=0.01) (Figure 2).  
 
All-cause mortality 
All-cause mortality was not affected by the treatment (OR 0.92, 95%CI 0.69-1.23, 
p=0.58, I
2
=37 %) (Figure 2). Limiting the analysis to indirect/unspecific drugs, we 
observed a statistically significant reduction of all-cause mortality (OR 0.69, 95%CI 0.52-
0.92, p=0.01, I
2
=0%) (Figure 2).  
 
Hospital readmission for heart failure 
Hospital readmissions for HF were significantly reduced (OR 0.64; 95%CI 0.45-
0.92, p=0.01, I
2
=59%) in patients randomly allocated to receive drugs targeting 
mitochondrial component/pathways (Figure 3). The overall effect was principally driven 
by studies of drugs with indirect/unspecific mechanism of action (OR 0.41; 95%CI 0.28-
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0.60; p<0.00001, I
2
=17% vs. OR 1.03, 95%CI 0.77-1.37, p=0.85, I
2
=15%, Chi
2
 test for the 
difference p=0.0002).  
 
Left ventricular ejection fraction 
The administration of drugs targeting mitochondrial function demonstrated an 
increase in LVEF as compared to placebo (OR 1.44; 95% CI 1.15-1.82; p=0.002, I
2
=80%) 
(Figure 3). This effect was due to studies randomizing to indirect/unspecific drugs (OR 
1.49, 95%CI 1.09-2.05, p=0.01) as compared to the others (OR 1.40, 95%CI 0.96-2.05, 
p=0.08), although the difference between the two subgroups did not reach statistical 
significance (p=0.8) (Figure 3).  
 
Additional analyses 
Additional analyses are detailed in the online appendix. Briefly, the administration 
of cyclosporine or nicorandil vs. placebo did not affect study outcomes (see Figure 1 and 
2 in Ref [27]). A reduction in hospital readmission for HF was more evident in studies 
with follow-up length ≥12 months (see Figure 4, 5 and 6 in Ref [27]). Excluding the study 
by Pizarro et al. (metoprolol) [15], we did not observe significant differences in our results 
(see Figure 3 in Ref [27]). Finally, random effects meta-regression disclosed no significant 
interaction between confounding factors and the administration of drugs targeting 
mitochondrial function and outcomes (Supplemental Table 3). Especially, baseline TIMI 
flow >1, thromboaspiration and glycoprotein IIbIIIa inhibitor did not affect the 
relationship between experimental drug and outcome.    
 
Publication bias 
There was no evidence of publication bias (supplemental online). 
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DISCUSSION. 
 
In the last decades, we observed a significant and progressive mortality reduction in STEMI 
patients receiving coronary reperfusion by primary PCI [1]. Nevertheless, mortality after STEMI is 
still not negligible and the number of patients developing HF is increasing [1-3,28]. As such, new 
treatments are clearly on demand to further reduce IS and preserve LVEF, thereby improving 
clinical outcome. A field of cardiovascular research pursuing this ambitious aim is termed 
“cardioprotection”, based on the hotly debated concept of lethal RI and on the application of 
strategies and/or drugs able to reduce it [2-5]. Although it is still debated by some authors, 
mitochondrial function is considered the crucial mediator of RI [4-5]. Consequently, it is not 
surprising that several RCTs with drugs targeting mitochondrial function have been conducted in 
the recent past [6-19]. The major characteristics of these studies can be summarized as follows: i) 
selection of agents against mitochondrial component/pathways; ii) positive results of the agent in 
preclinical investigations; iii) inclusion of selected series of STEMI patients being “proof-of 
concept” investigations; iv) surrogate markers of left ventricle (LV) salvage or LV function or IS as 
primary endpoint; v) absence of persuasive results to demonstrate the effectiveness of the 
experimental treatment. In addition, all of these trials were underpowered for hard clinical 
endpoints. The reasons for this failure are multiple and not the aim of our study [28]. Surely, 
discrepancies in the dose of the experimental drug, of the timing of its administration and of the 
patient’s selection (e.g. location of MI, spontaneous coronary reperfusion, time between symptom’s 
onset and reperfusion) played a crucial role in these mixed or neutral results [29]. 
The purpose of the present meta-analysis was to collect data from each RCT to assess the 
presence of benefit on hard endpoints deriving from the administration of experimental drug against 
mitochondrial component/pathways. The strengths of our work are the selection of agents, the 
adjudication of the mechanism of action by experts in the field of mitochondrial function, the 
collection of original data from authors, the largest sample size for a study in this topic and the low 
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degree of heterogeneity (expressed as I
2
%) in the majority of the analyses. Overall, we did not 
demonstrate a significant reduction in either cardiovascular or all-cause mortality. The 
administration of experimental drugs targeting mitochondrial function in STEMI patients did not 
affect mortality. This neutral effect was observed despite the significant improvement in LVEF and 
the reduction in HF hospital readmissions. We may speculate that the benefit in terms of LVEF 
preservation and HF reduction is too small to translate into a mortality advantage or that the study 
population and/or the number of deaths are not adequate to observe a significant difference. In 
addition, we have a follow-up length >12 months only in 7 studies and the short follow-up could be 
limited the benefit in terms of mortality due to HF hospital readmission reduction. 
The major novelty of our work is the focus on drugs targeting mitochondrial function. This 
is the first attempt to classify drugs according the mechanism of action against mitochondria and to 
investigate their effectiveness. The pathophysiological rationale derives from previous and recent 
studies suggesting that most critical subcellular signalling of lethal RI are located in mitochondria 
components and/or pathways [4-5]. Interestingly, we did not observe any benefit from the 
administration of drugs with a mechanism of action direct and selective for mitochondrial targets. 
Conversely, drugs with a broad-spectrum mechanism of action reduced all clinical endpoints, 
including cardiovascular and all-cause mortality. Furthermore, the findings were also confirmed 
after the exclusion of the study by Pizarro et al. where patients were randomized to metoprolol vs. 
placebo (questionable effect against mitochondrial targets) [15]. These findings could be interpreted 
as indirect evidence against RI. We may infer that RI is not important or that it is not a major 
determinant of prognosis in humans. Nicorandil, exenatide, metoprolol, nitrite, doxycycline and 
atrial natriuretic peptide have multiple physiological effects which could have improved LVEF or 
reduced mortality and HF, independently from any effect on RI [12-19]. Alternatively, the results of 
this study could be viewed as proof against mitochondrial involvement in RI. Nevertheless, we may 
hypothesize that the targets of drugs with presumed direct/selective mechanisms of action against 
mitochondria were in fact not directed primarily at key factors in the RI genesis, as recent evidence 
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suggest for cyclosporine and TRO40303 [4,30-31]. Finally, our findings should be also interpreted 
in context with the results from mechanical strategies of cardioprotection (post and remote 
conditioning) [32]. We cannot exclude that components and pathways involved in myocardial 
necrosis during myocardial ischemia and reperfusion are multiple. Accordingly, a broad-spectrum 
approach (e.g. the recently proposed “combination reperfusion therapy”) could be more effective as 
compared to a single-target approach [5]. Besides such intriguing speculations, further studies are 
clearly warranted either in pre-clinical and clinical setting [29-34].    
   
Study limitations 
Our results suffer from those limitations which are inherent to all meta-analytic techniques 
including particularly heterogeneity in patient populations, different study drug regimens, and 
variable endpoint definitions across studies. This mainly applies to the different criteria employed 
to assess IS. Due to variable definitions and methods (cardiac magnetic resonance, troponin T or I 
or creatine kinase release) across studies, we are not able to give a comprehensive estimate of effect 
on IS. In addition, despite the inclusion of 15 studies, our final study population (5680 STEMI 
patients) remains underpowered to draw final conclusions on mortality. Consequently, subgroup 
analyses should be considered hypothesis-generating and require further confirmations. Finally, 
since non-fatal endpoints were included in the analysis, competing risk should be accounted for in 
the analysis, but data to calculate them were not available.  
 
Conclusions 
Administration of drugs targeting mitochondrial function in STEMI patients undergoing primary 
PCI appear to have no effect on mortality, but may reduce hospital readmission for HF. The drugs 
with a broad-spectrum mechanism of action seem to be more effective in reducing adverse events. 
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FIGURE LEGENDS 
 
Figure 1. Flow diagram of the systematic literature search indicating the inclusion 
and exclusion process. 
STEMI: ST-segment elevation myocardial infarction. 
 
Figure 2. Forest plots on cardiovascular mortality and all-cause mortality 
SF: safety population. ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic 
peptide. NIC: nicorandil. CV: cardiovascular. 
 
Figure 3: Forest plots on hospital readmissions for heart failure and left ventricle 
ejection fraction. 
SF: safety population. ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic 
peptide. NIC: nicorandil. HF: heart failure. LVEF: left ventricle ejection fraction. 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Table 1. Main characteristics of the randomized clinical trials 
 Direct/selective mechanism of action against mitochondrial component/pathway Indirect/unspecific mechanism of action against mitochondrial component/pathway 
Study Piot Cung Ottani 
Lincoff 
ANT 
Lincoff 
INF 
Atar Gibson Ishii Lee 
Kitakaze 
NIC 
Kitakaze 
ANP 
Pizarro Longborg Jones Siddiqi Cerisano 
Pts randomized 58 970 410 1010 166 167 297 368 73 613 603 270 387 82 280 110 
Pts included in the 
analysis 
58 969 410 997 159 165 297 368 73 545 569 270 330 80 280 110 
Experimental drug CYC CYC CYC DEL DEL TRO40303 MTP131 NIC NIC NIC ANP metoprolol exenatide nitrite nitrite doxycycline 
Pts receiving 
experimental drug 
30 474 207 748 80 85 150 185 37 276 277 139 174 40 146 55 
Only anterior MI N Y N Y N N Y N N N N Y N N N N 
Max symptoms-
PCI time (h) 
12 12 6 6 6 6 4 24 12 12 12 6 12 6 12 12 
Prior MI exclusion 
criteria 
N N Y Y Y Y Y N Y Y Y Y Y Y Y Y 
Follow-up 
(months) 
3 12 6 3 3 1 6 27±15 1 30±13 32±12 24* 12 36 6 6 
LVEF  
(method) 
TTE TTE TTE TTE NA CMR CMR LVG NA LVG LVG CMR CMR CMR CMR TTE 
LVEF  
timing (months) 
3 12 6 3 NA 1 1 6 NA 6 6 6 3 6 6 6 
Age 
(years) 
58±2 60±12 63±13 60±8 61±8 62±12 60±11 58±2 
63±10 
58±12 62±10 63±10 58±11 63±11 57±12 63±13 
Male 
n. (%) 
46 (79) 795 (82) 327 (80) 
729 
(72) 
126 
(76) 
136 (83) 224 (75) 298 (81) 
61 (73) 
466 (76) 454 (75) 233 (86) 263 (80) 67 (84) 177 (77) 76 (69) 
Diabetes 
n. (%) 
8 (14) 123 (13) 58 (14) 
146 
(14) 
25 (15) 12 (7) 35 (14) 119 (32) 
23 (31) 
186 (30) 167 (28) 55 (20) 27 (8) 6 (8) 33 (14) 23 (21) 
Anterior MI 
 n. (%) 
24 (41) 969 (99) 203 (49) 
997 
(99) 
0 (0) 62 (38) 282 (98) 174 (47) 
40 (55) 
269 (44) 206 (34) 222 (82) 137 (42) 21 (26) 87 (38) 101 (92) 
Symptom-balloon 
time (minutes) 
302±28 
270±180 180±60 180±72 180±72 170±72 180±60 
282±180 360±180 
210±150 240±180 120±60 180±110 189±72 220±128 224±202 
Thromboaspiration 
n. (%) 
0 (0) 736 (76) 275 (67) NA NA NA 138 (48) 128 (35) 
0 (0) 
0 (0) 0 (0) 208 (77) 185 (56) 64 (80) 127 (45) 69 (63) 
GPI IIbIIIa 
n. (%) 
21 (36) 366 (38) 182 (44) 
474 
(47) 
80 (48) 66 (40) 159 (54) 0 (0) 
10 (14) 
0 (0) 0 (0) 191 (71) 270 (81) 
80 
(100) 
115 (41) 101 (92) 
TIMI pre 0-1 
n. (%) 
58 (100) 864 (89) 
410 
(100) 
547 
(54) 
111 
(68) 
163 (100) 147 (52) 311 (84) 
48 (66) 613 
(100) 
603 
(100) 
205 (76) 220 (67) 70 (87) 226 (81) 77 (70) 
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Pts: patients. MI: myocardial infarction. PCI: percutaneous coronary intervention. LVEF: left ventricle ejection fraction. TTE: 
transthoracic echocardiography. ANT: anterior cohort. INF: inferior cohort. CMR: cardiac magnetic resonance. LVG: left ventricle 
angiography.  ANP: atrial natriuretic peptide. NIC: nicorandil. NA: data not available/not assessed. Y: yes. N: not.  
*: median follow-up. GPI: glycoprotein inhibitor. TIMI: thrombolysis in myocardial infarction.  CYC: cyclosporine.  DEL: delcaserbib.
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Fig. 3 
